{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:57:09Z","timestamp":1788465429004,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10557-023-07481-w","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T12:47:26Z","timestamp":1687524446000},"page":"187-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sacubitril\/Valsartan in Dialysis Patients: Update on Current Perspectives"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-4776","authenticated-orcid":false,"given":"Leonardo","family":"Spatola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Zeiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"7481_CR1","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","volume":"298","author":"J Coresh","year":"2007","unstructured":"Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038\u2013204.","journal-title":"JAMA"},{"key":"7481_CR2","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, Hobbs FD. Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis. PLoS One. 2016;11:e0158765.","journal-title":"PLoS One"},{"key":"7481_CR3","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMra000050","volume":"345","author":"KT Weber","year":"2001","unstructured":"Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689\u201397.","journal-title":"N Engl J Med"},{"key":"7481_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/ki.2012.439","volume":"83","author":"S Ruiz","year":"2013","unstructured":"Ruiz S, Pergola PE, Zager RA, Vaziri ND. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 2013;83:1029\u201341.","journal-title":"Kidney Int."},{"key":"7481_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000349966","volume":"182","author":"PA McCullough","year":"2013","unstructured":"McCullough PA, Kellum JA, Haase M, et al. Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2013;182:82\u201398.","journal-title":"Contrib Nephrol"},{"issue":"12","key":"7481_CR6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2459\/JCM.0000000000001214","volume":"22","author":"L Spatola","year":"2021","unstructured":"Spatola L, Rivera RF, Migliore F, Bilato C, Mugnai G. Cardiovascular implantable electronic devices in hemodialysis patients: an updated review. J Cardiovasc Med (Hagerstown). 2021;22(12):867\u201373.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"7481_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"The SOLVD Investigators","year":"1991","unstructured":"The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293\u2013302.","journal-title":"N Engl J Med."},{"issue":"23","key":"7481_CR8","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429\u201335. PMID: 2883575","journal-title":"N Engl J Med"},{"key":"7481_CR9","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667\u201375.","journal-title":"N Engl J Med."},{"key":"7481_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"key":"7481_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380:539\u201348.","journal-title":"N Engl J Med"},{"issue":"17","key":"7481_CR12","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609\u201320.","journal-title":"N Engl J Med"},{"key":"7481_CR13","doi-asserted-by":"publisher","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.\u00a02017 ACC\/AHA\/HFSA Focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation. 2017;136(6):e137-e161. https:\/\/doi.org\/10.1161\/CIR.0000000000000509.","DOI":"10.1161\/CIR.0000000000000509"},{"issue":"1","key":"7481_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"TA McDonagh","year":"2022","unstructured":"ESC Scientific Document Group, McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24(1):4\u2013131. PMID: 35083827","journal-title":"Eur J Heart Fail"},{"key":"7481_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13036-017-0093-0","volume":"12","author":"S Fu","year":"2018","unstructured":"Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J. Biol. Eng. 2018;12:2.","journal-title":"J. Biol. Eng."},{"key":"7481_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","volume":"68","author":"A Bayes-Genis","year":"2016","unstructured":"Bayes-Genis A, Barallat J, Richards AM. A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol. 2016;68:639\u201353.","journal-title":"J Am Coll Cardiol"},{"key":"7481_CR17","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1136\/heartjnl-2017-311295","volume":"103","author":"JSS Singh","year":"2017","unstructured":"Singh JSS, Burrell LM, Cherif M, Squire IB, Clark AL, Lang CC. Sacubitril\/valsartan: beyond natriuretic peptides. Heart. 2017;103:1569\u201377.","journal-title":"Heart"},{"key":"7481_CR18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation. 2002;106:920\u20136.","journal-title":"Circulation"},{"key":"7481_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17","author":"JB Kostis","year":"2004","unstructured":"Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am. J. Hypertens. 2004;17:103\u201311.","journal-title":"Am. J. Hypertens."},{"key":"7481_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/ndt\/gfz058","volume":"35","author":"R Haynes","year":"2020","unstructured":"Haynes R, Zhu D, Judge PK, Herrington WG, Kalra PA, Baigent C. Chronic kidney disease, heart failure and neprilysin inhibition. Nephrol. Dial. Transplant. 2020;35:558\u201364.","journal-title":"Nephrol. Dial. Transplant."},{"key":"7481_CR21","doi-asserted-by":"publisher","first-page":"e00336","DOI":"10.1002\/prp2.336","volume":"5","author":"K Ushijima","year":"2017","unstructured":"Ushijima K, Ando H, Arakawa Y, Aizawa K, Suzuki C, Shimada K, Tsuruoka SI, Fujimura A. Prevention against renal damage in rats with subtotal nephrectomy by sacubitril\/valsartan (LCZ696), a dual-acting angiotensin receptor-neprilysin inhibitor. Pharmacol Res Perspect. 2017;5:e00336.","journal-title":"Pharmacol Res Perspect"},{"key":"7481_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cardfail.2017.12.010","volume":"24","author":"Y Suematsu","year":"2018","unstructured":"Suematsu Y, Jing W, Nunes A, Kashyap ML, Khazaeli M, Vaziri ND, Moradi H. LCZ696 (Sacubitril\/Valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease. J Card Fail. 2018;24:266\u201375.","journal-title":"J Card Fail"},{"key":"7481_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijcard.2015.03.116","volume":"186","author":"BH Wang","year":"2015","unstructured":"Wang BH, Von Lueder TG, Kompa AR, Li H, Webb R, Jordaan P, Atar D, Krum H. Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis. Int J Cardiol. 2015;186:104\u20135.","journal-title":"Int J Cardiol"},{"key":"7481_CR24","doi-asserted-by":"crossref","first-page":"B5","DOI":"10.1681\/ASN.2016060664","volume":"28","author":"R Haynes","year":"2017","unstructured":"Haynes R, Judge PK, Staplin N, Landray MJ, Baigent C. Results of a randomized multicentre pilot study of sacubitril\/valsartan versus irbesartan in patients with CKD: United Kingdom heart and renal protection (UK HARP)-III trial. J Am Soc Nephrol. 2017;28:B5.","journal-title":"J Am Soc Nephrol"},{"key":"7481_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","volume":"99","author":"AK Cheung","year":"2021","unstructured":"Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, Knoll GA, Muntner P, Pecoits-Filho R, Sarnak MJ, Tobe SW, Tomson CRV, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli M, Cheung M, Earley A, Mann JFE. Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99:559\u201369.","journal-title":"Kidney Int."},{"key":"7481_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","volume":"74","author":"HY Chang","year":"2019","unstructured":"Chang HY, Feng AN, Fong MC, Hsueh CW, Lai WT, Huang KC, Chong E, Chen CN, Chang HC, Yin WH. Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol. 2019;74:372\u201380.","journal-title":"J Cardiol"},{"issue":"18","key":"7481_CR27","doi-asserted-by":"publisher","first-page":"e026407","DOI":"10.1161\/JAHA.122.026407","volume":"11","author":"C-Y Niu","year":"2022","unstructured":"Niu C-Y, Yang S-F, Ou S-M, Wu C-H, Huang P-H, Hung C-L, Lin C-C, Li S-Y. Sacubitril\/Valsartan in patients with heart failure and concomitant end-stage kidney disease. J Am Heart Assoc. 2022;11(18):e026407. Epub 2022 Sep 5","journal-title":"J Am Heart Assoc"},{"key":"7481_CR28","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/ehf2.12659","volume":"7","author":"S Lee","year":"2020","unstructured":"Lee S, Oh J, Kim H, Ha J, Chun KH, Lee CJ, Park S, Lee SH, Kang SM. Sacubitril\/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. ESC Heart Fail. 2020;7:1125\u20139.","journal-title":"ESC Heart Fail"},{"key":"7481_CR29","doi-asserted-by":"crossref","unstructured":"Heyse A, Manhaeghe L, Mahieu E, Vanfraechem C, Van Durme F. Sacubitril\/valsartan in heart failure and end-stage renal insufficiency. ESC Heart Fail. 2019;6(6):1331-1333.\u00a0 Epub 2019 Oct 30.PMID: 31668014.","DOI":"10.1002\/ehf2.12544"},{"issue":"9","key":"7481_CR30","doi-asserted-by":"publisher","first-page":"794707","DOI":"10.3389\/fcvm.2022.794707","volume":"8","author":"FC Hsiao","year":"2022","unstructured":"Hsiao FC, Lin CP, Yu CC, Tung YC, Chu PH, et al. Front Cardiovasc Med. 2022;8(9):794707. eCollection 2022","journal-title":"Front Cardiovasc Med."},{"key":"7481_CR31","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00228-016-2072-7","volume":"72","author":"SP Ayalasomayajula","year":"2016","unstructured":"Ayalasomayajula SP, Langenickel TH, Jordaan P, Zhou W, Chandra P, Albrecht D, Pal P, Rajman I, Sunkara G. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril\/valsartan), an angiotensin receptor neprilysin inhibitor. Eur J Clin Pharmacol. 2016;72:1065\u201373.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07481-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07481-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07481-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T04:18:41Z","timestamp":1738815521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07481-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["7481"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07481-w","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"assertion":[{"value":"11 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval is not requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"No consent to participate was necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The manuscript is a narrative revision, and no written consent was requested to prepare it.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"No consent for publication was requested.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}